Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Diabetes significantly increases the risk of bone diseases like osteoporosis, leading to fractures even with normal bone ...

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...

The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial.